FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

shington,	D.C.	20549	

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* RIEFLIN WILLIAM JL					2. Issuer Name and Ticker or Trading Symbol Lyell Immunopharma, Inc. [LYEL]									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	,	rst)	3. Date of Earliest Transaction (Month/Day/Year) 06/16/2023								Of		(give title		Other (s below)				
C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) SOUTH SAN CA 94080				Form filed by More than Person										•					
FRANCISCO CA 54000					-	Rule 10b5-1(c) Transaction Indication													
(City)	(S	tate)	(Zip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									d to				
		Tab	le I - Noi	n-Deriva	ative	Sec	curities	Ac	quired, D	ispo	osed o	of, or Be	neficia	lly Ow	ned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,		Transaction Disposed Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 au		and Securitie Benefici Owned F		es For ally (D) Following (I) (rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	Amount (A) or P		Trai	Reported Transaction(s) (Instr. 3 and 4)				nstr. 4)	
		Т							uired, Dis , options					y Own	ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date, 1	Code (Instr				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		piration te	Amour or Number of Title Shares							
Option (right to buy)	\$3.19	06/16/2023			A		65,000		(1)	06/3	15/2033	Common Stock	65,000	\$0.0	0	65,000		D	

1. The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date.

Remarks:

/s/ Charles Newton, as Attorney-in-Fact

06/20/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.